Inicio・Lista de Acciones・Travere Therapeutics Inc

Travere Therapeutics Inc

Cerrado

65.42 1.9

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

65.23

Máximo

65.98

Métricas clave
By Trading Economics
Ingresos	1.8M -35M
Ventas	42M 170M
BPA	-0.37
Margen de beneficios	-20.519
Empleados	497
EBITDA	-24M -33M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+13.64% upside

Dividendos
By Acuity
Próximas Ganancias	29 oct 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	876M 6B
Apertura anterior	63.52
Cierre anterior	65.42

Travere Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 ago 2026, 23:51 UTC

RBA Meeting Minutes Release on August 25, 2026, Sparks Cautious Market Sentiment Amid Persistent Inflation and Economic Cooling in Australia.

22 ago 2026, 23:51 UTC

Macro News

Bitcoin is trading lower during Saturday's session, despite earlier rising above $70,000, amid ongoing geopolitical tensions and pressures in the bond market.

22 ago 2026, 23:41 UTC

Bitcoin and Ethereum decline as rising bond yields raise concerns over economic growth and investor sentiment shifts towards safer assets.

22 ago 2026, 23:41 UTC

Cryptocurrency Prices Drop Amid Rising Bond Yields and Geopolitical Tensions, Impacting Market Sentiment.

22 ago 2026, 23:41 UTC

Cryptocurrency Markets Decline Amid Rising Bond Yields and Economic Pressures, with Ethereum Down 3.9% and Bitcoin 1.7%.

22 ago 2026, 23:41 UTC

Bitcoin and Ethereum decline as rising bond yields and inflation concerns pressure risk assets amid mixed global market performance.

22 ago 2026, 23:41 UTC

U.S. Goods Trade Balance Expected to Show $99 Billion Deficit Amidst Rising Tariff Tensions with Canada

22 ago 2026, 23:41 UTC

Upcoming U.S. Retail Inventories Ex Autos Data Release on August 27, 2026, Expected to Impact Market Sentiment Amid Cautious Investor Outlook.

22 ago 2026, 23:41 UTC

U.S. Wholesale Inventories Expected to Rise 0.1% Amid Caution Over Economic Conditions and Market Volatility

22 ago 2026, 23:41 UTC

Canada's Current Account Deficit Expected to Widen to -5.5 Billion CAD Amid Trade Negotiation Uncertainties with the U.S.

22 ago 2026, 23:41 UTC

Terra is trading lower today, reversing three consecutive sessions of gains. The asset has declined significantly since Friday's close, with no specific news identified.

22 ago 2026, 23:31 UTC

US GDP Price Index QoQ 2nd Estimate on August 26 Forecasts 0.063% Increase Amid Rising Oil Prices and Optimistic Q3 Growth Outlook

22 ago 2026, 23:31 UTC

South Africa's Balance of Trade Data Set for Release Amidst Investor Optimism Following Recent Surplus Growth and Global Economic Pressures.

22 ago 2026, 23:31 UTC

U.S. Home Prices Expected to Rise 1.7% YoY Amid Mixed Economic Sentiment and Market Volatility

22 ago 2026, 23:21 UTC

Market braces for July 2026 PCE Price Index release, with a modest +0.1% increase forecast amid mixed inflation sentiment and external economic pressures.

22 ago 2026, 23:21 UTC

PCE Price Index Release on August 26, 2026: Key Inflation Indicator Amid Market Volatility and Fed Policy Concerns.

22 ago 2026, 23:21 UTC

U.S. Personal Income Expected to Rise 0.3% in August Amid Cautious Market Sentiment and Consumer Spending Concerns

22 ago 2026, 23:21 UTC

U.S. Personal Spending Forecasted to Rise 0.2% in August Amid Mixed Economic Signals and Inflation Concerns

22 ago 2026, 23:21 UTC

Core PCE Price Index MoM for July 2026 set to release on August 26, with a forecasted increase of 0.2%, amid rising oil prices and geopolitical tensions influencing market sentiment.

22 ago 2026, 23:21 UTC

U.S. Durable Goods Orders Ex Transportation Expected to Rise 0.5% Amid Economic Caution and Upcoming Market Influences

22 ago 2026, 23:21 UTC

U.S. Durable Goods Orders Expected to Rise 0.7% Amid Economic Volatility and Geopolitical Tensions, with Market Cautiously Optimistic Ahead of Jackson Hole Symposium

22 ago 2026, 23:21 UTC

U.S. GDP Growth Rate Expected at +1.5% for Q2 2026 Amid Optimistic Economic Indicators and Fed's Revised Forecast of +2.3% for Q3

22 ago 2026, 23:21 UTC

U.S. Corporate Profits Report for Q2 2026 Set to Release Amid Economic Uncertainty and Market Volatility on August 26.

22 ago 2026, 23:11 UTC

ECB Meeting Accounts Set for Release Amid Market Anticipation of Interest Rate Signals and Inflation Trends on August 27, 2026.

22 ago 2026, 23:11 UTC

Mexico's Trade Balance Expected to Show Continued Surplus Amid U.S.-Canada Negotiation Uncertainty Ahead of August 27 Data Release.

22 ago 2026, 23:11 UTC

Brazil's Unemployment Rate Set for Release Amid Optimistic Market Sentiment Following June Drop to 5.4%

22 ago 2026, 23:11 UTC

News

Ethereum is lower today, continuing a decline since Friday's close. Earlier, the asset reached a session low before recovering slightly.

22 ago 2026, 23:11 UTC

Correlated Moves

Avalanche is declining today, influenced by a drop in correlated asset Ethereum. The asset's recent strong performance contrasts with today's downturn during the session.

22 ago 2026, 23:11 UTC

News

Ethereum is lower during Saturday's session, reflecting a significant drop since Friday's close. The asset reached a session low earlier today.

22 ago 2026, 23:01 UTC

Macro News

The DAX 30 Index is declining after the U.S. imposed 50% tariffs on Canadian goods, worsening trade relations and impacting investor sentiment.

Comparación entre iguales

Cambio de precio

Travere Therapeutics Inc previsión

Precio Objetivo

By TipRanks

13.64% repunte

Estimación a 12 Meses

Media 74.67 USD 13.64%

Máximo 90 USD

Mínimo 62 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Travere Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para Travere Therapeutics Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.